Dendreon shares slip as investors check enthusiasm

The rapid mood swings of biotech investors was evident this morning as shares of Dendreon slumped 8.4 percent on worries that the stock price had climbed too high. Dendreon's share price had tripled in the days after an FDA expert committee voted in favor of its prostate therapy Provenge. Some analysts are betting that the FDA--which will make the final decision on Provenge by May 15--will either give it a complete approval or issue an approvable letter looking for additional data. In the meantime, the share price remains highly volatile.

- read the Forbes report on the stock swing

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.